Coherus BioSciences Outlines Cost-Saving Measures and Revised Cash Burn Targets
Coherus BioSciences (CHRS) has announced a strategic shift aimed at achieving financial self-sufficiency. The company expects to realize quarterly savings between $6 million and $7 million as part of its ongoing restructuring efforts. In addition to cost reductions, management has lowered the projected cash burn support target for LOQTORZI to a range of $25 million to $30 million per quarter. CEO Dennis Lanfear stated that the company is currently pursuing three strategic alternatives intended to transform Coherus into a self-sustaining oncology firm focused on best-in-class and first-in-class products.
Tickers: $CHRS
Topics: earnings call financial restructuring oncology strategic alternatives
Read the full article at Seeking Alpha
Part of the story Coherus Oncology Announces Workforce Reductions and Strategic Clinical Shift (3 articles)